In brief
- Benefits from multiple inventions or patents may be considered together when assessing employee-inventor compensation. This should assist employees whose inventions may have contributed to creating an outstanding benefit cumulatively, but might not meet that threshold if assessed individually.
- Aggregation of inventions is not automatic: the employee must identify sensible combinations and explain why they should be assessed together.
- The parties’ financial positions must be considered at the costs-budgeting stage for this kind of dispute.
- Despite resolving both appeals, the court concluded that the legislation relating to employee-inventor compensation is “not fit for purpose” and needs rethinking.
The dispute
The employee-inventor compensation regime introduced by the Patents Act 1977 (the Act) gives employees a route to a fair share of the outstanding benefit their patented inventions bring to their employer, where it is just to award compensation.
In Parsons v Convatec Ltd, the Court of Appeal addressed two questions arising from an employee-inventor compensation claim by Dr Parsons, an analytical chemist employed by Convatec for 32 years, who claims credit for inventions across seven patent families concerning antimicrobial wound dressings. Proceedings began in September 2022, and a 37-day trial is listed for February 2028.
Under section 40(1) of the Act, an employee who has made a patented invention belonging to their employer may be awarded compensation where the invention, the patent, or both are of outstanding benefit to the employer and it would be just to award compensation to the employee in those circumstances (for patent applications filed before 1 January 2005, the outstanding benefit must derive from the patent – this portfolio spans both regimes). Outstanding benefit is assessed having regard, among other things, to the size and nature of the employer’s undertaking. Dr Parsons alleges that his inventions have generated an outstanding benefit, pointing to estimated global sales of relevant products by Convatec of around $3.2 billion to 2021. Convatec disputes the claim, including aspects of inventorship; neither entitlement to compensation nor its amount was determined on these appeals.
The questions before the Court of Appeal were:
- whether benefits from multiple inventions or patents could be assessed together, and
- whether the parties’ financial positions must be taken into account when approving costs budgets.
Multiple inventions and outstanding benefit
Convatec argued that each invention or patent must independently provide outstanding benefit under section 40(1) of the Act, emphasising that the remedy was reserved for exceptional, rather than routine, inventions. Dr Parsons sought to rely on the combined benefit of several inventions or patents.
The point has considerable financial significance: Dr Parsons relies on estimated global sales of around $3.2 billion to 2021 and values his claim at up to £366 million. Assessing the benefits together allows him to argue that the inventions or patents were of outstanding benefit in combination, even if not all of them (or even none, as Convatec contends) met that threshold on its own. Whether they should be assessed together on the facts of his case remains for trial.
The court held that combination of benefits accruing from multiple inventions and/or multiple patents was permissible. This reflects the relationship between inventions, patents and commercial products in practice: one patent may cover several inventions, several patents may protect one invention, and complementary inventions may contribute jointly to commercial success. Separating their benefits from each other along individual invention or patent lines might be artificial or unworkable, depending on the invention(s) and benefit in question.
However, this conclusion also carried a clear case-management warning. Dr Parsons must specify the combinations relied on as having led to an outstanding benefit, and why, well before trial, and must take a "sensible approach" rather than pursuing every permutation of them. Convatec must then identify its responses. Permission to aggregate multiple inventions together should not become a means of further expanding litigation that is already extensive (with six interim High Court judgments having been handed down already, since 2023).
Costs budgeting is part of determining costs
Costs budgeting involves the court reviewing and managing the parties’ estimated future costs for each phase of the litigation. Although this claim would not normally have been subject to costs management because its value exceeds £10 million, Dr Parsons proposed it and Convatec agreed. His principal reason given for doing so was the need to obtain insurance against an adverse costs order, but cost budgeting and approval can also introduce certainty and predictability around costs awards to be made at a later stage.
Under section 106(1) of the Act, the court must have regard to all relevant circumstances, including the parties’ financial positions, when determining whether to award costs and what costs to award in employee compensation proceedings. The second appeal concerned whether that requirement also applies when approving costs budgets.
The court held that section 106(1) applies when approving budgets, explaining that the evaluation of what costs to award embraces each step on the "critical path" to that ultimate decision, including the earlier procedural stage of budgeting. The key reason for this decision was that approved budgets are binding upon and constrain subsequent standard-basis assessment unless there is good reason to depart from them. Budgeting therefore forms part of a linked sequence leading to the ultimate costs award, even though it is not conclusive and does not cover costs already incurred at the time of the budget.
Excluding section 106 at the budgeting stage would potentially create an awkward consequence: the employee’s existing financial position would be left for later consideration. The judgment did not decide whether earlier non-consideration of the financial position would constitute "good reason" to depart from an approved budget, but taking it into account at the budgeting stage simply avoids that uncertainty. Whether or not there a good reason for departing from a previously approved cost budget will be a matter for each individual case, but previous guidance from the Court of Appeal has confirmed this is a significant fetter on unrestricted discretion, and deliberately so: an "indulgent" approach is discouraged.
The court also recognised that uncertainty over an individual employee’s exposure to adverse costs could drive up insurance premiums or litigation funding charges, substantially reducing the compensation retained even if their claim is successful.
The court recognised the employee’s need for meaningful advance certainty about costs exposure and reduced Convatec’s budgeted future costs from approximately £6.5 million to £4 million.
Comment: uncertainty and an unsatisfactory statutory framework
It is not hard to see why the question of employee compensation in general can create uncertainty and friction for both employees and employers in innovative industries. The statutory framework which allows for compensation for outstanding benefit can allow for substantial derogation from previously agreed contractual positions as between employers and employees, even where the invention belongs to the employer and the employee had been employed to invent (including to render certain clauses unenforceable under section 42 of the Act) – inevitably introducing a measure of uncertainty. An inevitable difficulty for both sides will be predicting when the outstanding benefit threshold will be met and what compensation should follow.
The postscript to this particular Court of Appeal judgment is stark. Almost 50 years after enactment of the applicable law, only two employee claims that have reached the courts had succeeded (a number will, of course, have been settled outside of or without the need for court proceedings), and the current litigation had already involved three unsuccessful mediations and extraordinary delay. Arnold LJ identified uncertainty in the legislation as the fundamental problem, noting that the law is "not fit for purpose" and "needs re-thinking". Both employers and employees would benefit from a clearer, more predictable framework.
How Mishcon de Reya can help
Our Patents and Employment teams advise businesses and individuals on protecting and commercialising employee inventions, including questions of inventorship, patent ownership and employee compensation. Where disputes arise, we can advise on the strategic and litigation issues involved, drawing on our experience acting for both employers and employees.